bogO, I sold some today, happy to pay more for them AFTER approval. Or buy them back cheap if not. Only 3 things can happen and 2 of them are not friendly to shareholders. Samrt and experienced investors know this. FOMO kills capital in biotech most of the time. naders history is not our friend no matter how much I believe in the science.